CLINICAL TRIALS PROFILE FOR PLENAXIS
✉ Email this page to a colleague
All Clinical Trials for PLENAXIS
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00100243 ↗ | Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy | Completed | PRAECIS Pharmaceuticals Inc. | Phase 2 | 2004-05-01 | This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg). |
NCT00103623 ↗ | The Plenaxis® Experience Study | Suspended | PRAECIS Pharmaceuticals Inc. | Phase 4 | 2004-06-01 | Praecis is currently conducting a 2000 patient Experience Study; this is a Phase IV commitment postmarketing safety study in the Food and Drug Administration (FDA) indicated population of patients receiving Plenaxis®. The purpose of the study is to estimate the incidence of immediate-onset systemic allergic reactions in the indicated population receiving Plenaxis® and to determine whether the hazard rate changes over time. |
NCT00841113 ↗ | Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer | Completed | Speciality European Pharma Limited | Phase 3 | 1999-01-01 | To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for PLENAXIS
Condition Name
Clinical Trial Locations for PLENAXIS
Trials by Country
Clinical Trial Progress for PLENAXIS
Clinical Trial Phase
Clinical Trial Sponsors for PLENAXIS
Sponsor Name